论文部分内容阅读
32例初诊2型糖尿病患者随机分为CSII组和CSII合用罗格列酮组强化治疗4周以评价其临床疗效,结果发现CSII合用罗格列酮组胰岛素用量少(P<0.01),IAI明显增加(P<0.01),且无严重低血糖反应、肝肾功能损害等副作用。结论:CSII合用罗格列酮治疗初发2型糖尿病更能有效地控制血糖、减轻胰岛素抵抗和改善胰岛β细胞功能。
Thirty-two newly diagnosed type 2 diabetic patients were randomly divided into CSII group and CSII combined with rosiglitazone group for 4 weeks to evaluate their clinical efficacy. The results showed that insulin combined with CSII combined rosiglitazone group had less insulin (P <0.01), IAI (P <0.01), and no serious hypoglycemic reaction, liver and kidney dysfunction and other side effects. CONCLUSIONS: CSII combined with rosiglitazone in the treatment of newly diagnosed type 2 diabetes is more effective in controlling blood glucose, reducing insulin resistance and improving pancreatic β-cell function.